Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000259790

Medchemexpress LLC Enbezotinib (TPX-0046) | 2359649-81-1 | 99.5% | C21H21FN6O3 | 10MG
SDP

Catalog No. 5000259790
Encompass_Preferred

Enbezotinib is a small-molecule RET kinase inhibitor used in preclinical cancer research. It inhibits RET autophosphorylation and is applied in studies of RET-driven tumors and signaling pathways. Supplied as a solid, it is intended for biochemical and cellular assay applications requiring a defined chemical standard.

  • Inhibits RET autophosphorylation for RET-targeted research.
  • High purity suitable for biochemical and cellular assays.
  • Solid form convenient for storage and handling.
  • Molecular weight 424.4 g/mol and defined formula for analytical use.
  • Useful in preclinical studies of RET-driven cancers.

Catalog No. 50-002-59790 Supplier Medchemexpress LLC Supplier No. HY14556510MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Enbezotinib is a small-molecule RET kinase inhibitor used in preclinical cancer research. It inhibits RET autophosphorylation and is applied in studies of RET-driven tumors and signaling pathways. Supplied as a solid, it is intended for biochemical and cellular assay applications requiring a defined chemical standard.

  • Inhibits RET autophosphorylation for RET-targeted research.
  • High purity suitable for biochemical and cellular assays.
  • Solid form convenient for storage and handling.
  • Molecular weight 424.4 g/mol and defined formula for analytical use.
  • Useful in preclinical studies of RET-driven cancers.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.